Amgen (AMGN) PT Raised to $362 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Stocks expected to have increasing option volume: AMGN ABNB FTNT SMCI RIVN TOST RDDT WYNN VFC CRUS IAC TRIP
August 7, 2024 5:03 AM EDTStocks expected to have increasing option volume: AMGN ABNB FTNT SMCI RIVN TOST RDDT WYNN VFC CRUS IAC TRIP
... MoreWells Fargo Downgrades Amgen (AMGN) to Equal Weight
August 7, 2024 3:33 AM EDTWells Fargo analyst Mohit Bansal downgraded Amgen (NASDAQ: AMGN) from Overweight to Equal Weight with a price target of $335.00 (from $320.00).
The analyst comments: "We are downgrading AMGN to Equal Weight with $335/sh PT because we think the Street is already giving them... More
Amgen quarterly profit slips, obesity data on track for late 2024
August 6, 2024 4:05 PM EDTBy Deena Beasley
(Reuters) -Amgen on Tuesday said its second-quarter profit slipped 1% as higher expenses, including costs related to development of its experimental obesity drug MariTide, offset a 20% increase in revenue driven by the biotechnology company's October acquisition of rare disease drugmaker Horizon Therapeutics.
Amgen reported adjusted earnings of $4.97 per share, which was 3 cents shy of the average analyst estimate, according to LSEG data.
Quarterly revenue of $8.39 billion was slightly ahead of the $8.37 billion forecast by analysts.
"The quarter overall looks fairly uneventful," Mizuho... More
Amgen (AMGN) Misses Q2 EPS by 1c; updates guidance
August 6, 2024 4:03 PM EDTAmgen (NASDAQ: AMGN) reported Q2 EPS of $4.97, $0.01 worse than the analyst estimate of $4.98. Revenue for the quarter came in at $8.39 billion versus the consensus estimate of $8.35 billion.
GUIDANCE:
Amgen sees FY2024 EPS of $19.10-$20.10, versus the consensus of $17.87. Amgen sees... More
